EcoDrugPlus

Akt Serine/threonine Kinase 2

Ensembl ID : ENSCDRG00005010340
Gene Symbol: AKT2
1 Cross references
257 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSCDRG00005013167
Gene Symbol: AKT3
2 Cross references
200 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSCDRG00005013130
Gene Symbol: ALK
1 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSCDRG00005020429
Gene Symbol: ABCB1
1 Cross references
161 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSCDRG00005015181
Gene Symbol: ABCC1
1 Cross references
203 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSCDRG00005014728
Gene Symbol: ABCC8
3 Cross references
245 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSCDRG00005018701
Gene Symbol: ABCC9
3 Cross references
233 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSCDRG00005004105
Gene Symbol: ATP4A
3 Cross references
183 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSCDRG00005011261
Gene Symbol: ATP4B
3 Cross references
171 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSCDRG00005003442
Gene Symbol: ATP1A1
3 Cross references
328 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 2

Ensembl ID : ENSCDRG00005011929
Gene Symbol: ATP1A2
3 Cross references
207 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSCDRG00005018181
Gene Symbol: ATP1A3
1 Cross references
134 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).